Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ: TSVT )

4.770 +0.330 (+7.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 544,213
Open 4.450
Bid (Size) 4.700 (1)
Ask (Size) 4.800 (1)
Prev. Close 4.440
Today's Range 4.410 - 4.850
52wk Range 1.535 - 10.89
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Hidden Stock Gems That Wall Street Is Overlooking
If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. 
Via InvestorPlace
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
Via Benzinga

Performance

YTD
+16.34%
+16.34%
1 Month
+16.91%
+16.91%
3 Month
-4.31%
-4.31%
6 Month
+36.29%
+36.29%
1 Year
-53.87%
-53.87%

More News

Read More
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
A Preview Of 2seventy bio's Earnings
Via Benzinga
TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
From 2seventy bio, Inc.
Via Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Via Benzinga
Exposures Product Safety
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
Via Benzinga
Exposures Product Safety
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Via Benzinga
TSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
Earnings Scheduled For March 5, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.